What is the Role of HTA for Biosimilars?
![396 - 2014 Role-of-HTA-for-Biosimilars-Mestre-Ferrandiz-Jul2015](https://www.ohe.org/wp-content/uploads/2015/07/396-2014-Role-of-HTA-for-Biosimilars-Mestre-Ferrandiz-Jul2015.jpg)
The speaker for the OHE’s 17th Annual Lecture was Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research at the School of Medicine. His remarks focused on the national health care legislation enacted in March 2010 in the US from a unique perspective – as a practicing professor of medicine, one of the world’s leading health economists, and an expert in health care policy. His overview touched on several of the key issues raised by the new law that relate to coverage, cost, and quality.
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!